Our public sector differential-pricing policy is part of our commitment to addressing HIV through a multi-pronged strategy, with the goal of ensuring that our HIV antiretroviral (ARV) medicines reach as many of those in need as possible.

We offer our lowest access price for our HIV medicines to countries based on a combination of highest disease burden and lower country income (gross national income [GNI] per capita), as defined by the World Bank. A list of eligible access countries is provided here.